Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:00 PM
Ignite Modification Date:
2025-12-24 @ 10:00 PM
NCT ID:
NCT02351232
Eligibility Criteria:
Inclusion Criteria:
* Type 1 diabetes ≥ 1 year
* BMI \> 25 kg/m2
* Insulin pump ≥ 1 year
* HbA1c \> 58 mmol/mol
* Use of carbohydrate counting and the insulin pump bolus calculator
Exclusion Criteria:
* Gastroparesis
* Impaired renal function (eGFR \< 60 ml/min/1.73m2)
* Liver disease with ALAT \> 2.5 times the upper limit of the reference interval
* Acute or chronic pancreatitis or history of chronic pancreatitis or idiopathic acute pancreatitis
* Inflammatory bowel disease
* History of cancer (except basal cell skin cancer) which in the investigators opinion could interfere with the results of the trial, or cancer during the past 5 years
* Thyroid adenoma
* Subjects with personal or family history of MTC or MEN2
* Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start
* Known or suspected alcohol or drug abuse
* Other concomitant medical or psychological condition that according to the investigator's assessment makes the patient unsuitable for study participation
* Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods.
* Simultaneous participation in any other clinical intervention trial
* Known or suspected hypersensitivity to Liraglutide
* Inability to understand the patient information and to give informed consent
* Acute treatment required proliferative retinopathy or maculopathy (macular oedema)
* Any Cardiac disorder which in the investigators opinion could interfere with the safety and results of the trial.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
70 Years
Study:
NCT02351232
Study Brief:
Protocol Section:
NCT02351232